Suppr超能文献

唑来膦酸输注继发双侧膝关节积液

Bilateral Knee Effusions Secondary to Zoledronic Acid Infusion.

作者信息

Wei Jenny, Cho Catherine Soo Ihn

机构信息

Rheumatology Department, Concord Repatriation General Hospital, Concord, NSW 2139, Australia.

出版信息

JCEM Case Rep. 2024 Oct 25;2(11):luae199. doi: 10.1210/jcemcr/luae199. eCollection 2024 Nov.

Abstract

Intravenous zoledronic acid is an established and generally well tolerated form of antiresorptive therapy for osteoporosis. Although mild arthralgias are a well-documented manifestation of the acute phase response to intravenous bisphosphonates, more severe musculoskeletal reactions manifesting as debilitating pain and joint effusions have been rarely documented in the current literature. In this case report, we discuss the case of a 55-year-old woman who developed severe painful bilateral knee effusions within 1 week of her first zoledronic acid infusion for osteoporosis. Prescribing physicians and patients should be made aware of this uncommon but important adverse effect to zoledronic acid.

摘要

静脉注射唑来膦酸是一种已确立的、普遍耐受性良好的抗骨质疏松症抗吸收治疗方式。虽然轻度关节痛是静脉注射双膦酸盐急性期反应的一种有充分记录的表现,但目前文献中很少记录到表现为使人衰弱的疼痛和关节积液的更严重肌肉骨骼反应。在本病例报告中,我们讨论了一名55岁女性的病例,她在首次因骨质疏松症输注唑来膦酸后1周内出现了严重的双侧膝关节疼痛性积液。开处方的医生和患者应了解唑来膦酸这种罕见但重要的不良反应。

相似文献

1
Bilateral Knee Effusions Secondary to Zoledronic Acid Infusion.
JCEM Case Rep. 2024 Oct 25;2(11):luae199. doi: 10.1210/jcemcr/luae199. eCollection 2024 Nov.
2
Flare-up of hand osteoarthritis caused by zoledronic acid infusion.
Osteoporos Int. 2010 Sep;21(9):1617-9. doi: 10.1007/s00198-009-1123-7. Epub 2009 Nov 21.
6
Adrenal Crisis as An Adverse Reaction to Zoledronic Acid in a Patient With Primary Adrenal Insufficiency: A Case Report and Literature Review.
AACE Clin Case Rep. 2022 Dec 17;9(2):32-34. doi: 10.1016/j.aace.2022.12.003. eCollection 2023 Mar-Apr.
8
Zoledronic acid in osteoporosis secondary to mastocytosis.
Am J Med. 2014 Nov;127(11):1127.e1-1127.e4. doi: 10.1016/j.amjmed.2014.06.015. Epub 2014 Jun 20.
10
Severe sepsis induced by zoledronic acid: A case report.
Medicine (Baltimore). 2024 Aug 30;103(35):e39188. doi: 10.1097/MD.0000000000039188.

本文引用的文献

2
OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis.
Osteoarthritis Cartilage. 2019 Nov;27(11):1578-1589. doi: 10.1016/j.joca.2019.06.011. Epub 2019 Jul 3.
4
Severe polyarthritis secondary to zolendronic acid: a case report and literature review.
Clin Cases Miner Bone Metab. 2015 Jan-Apr;12(1):69-74. doi: 10.11138/ccmbm/2015.12.1.069.
5
Flare-up of hand osteoarthritis caused by zoledronic acid infusion.
Osteoporos Int. 2010 Sep;21(9):1617-9. doi: 10.1007/s00198-009-1123-7. Epub 2009 Nov 21.
6
Adverse effects of bisphosphonates: implications for osteoporosis management.
Mayo Clin Proc. 2009 Jul;84(7):632-7; quiz 638. doi: 10.1016/S0025-6196(11)60752-0.
7
Bisphosphonates: mechanism of action and role in clinical practice.
Mayo Clin Proc. 2008 Sep;83(9):1032-45. doi: 10.4065/83.9.1032.
8
Significance and impact of bisphosphonate-induced acute phase responses.
J Oncol Pharm Pract. 2007 Dec;13(4):223-9. doi: 10.1177/1078155207080806.
9
Bisphosphonate-associated arthritis.
J Clin Rheumatol. 2006 Jun;12(3):131-3. doi: 10.1097/01.rhu.0000221796.06383.4e.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验